drugset / Trial / NCT00793598
CMX001 in Post-transplant Patients With BK Virus Viruria
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brincidofovir | Other / unclassified | 10 mg | Oral |
| Subject | Brincidofovir | Other / unclassified | 20 mg | Oral |
| Subject | Brincidofovir | Other / unclassified | 40 mg | Oral |
Indications
No indication recorded.